Drug Details

General Information of the Drug (ID: DR0167)
Name
GC-SF
Molecular Type
Protein
Disease Acute myelogenous leukemia [ICD-11: 2A41] Approved [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Aclarubicin      Streptomyces galilaeus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 Increasing the dose of aclarubicin in CAG regimen seemed to be useful and relatively safe in relapsed and refractory AML.
Target and Pathway
Target(s) Interleukin-20 receptor alpha (IL20RA)  Molecule Info  [3]
Interleukin-20 receptor beta (IL20RB)  Molecule Info  [3]
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015
Reference 2 Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia. Int J Hematol. 2014;99(5):603-8.
Reference 3 IL-24: A new player in the pathogenesis of pro-inflammatory and allergic skin diseases. Allergol Int. 2020 Jul;69(3):405-411.
 Download Picture         KEGG Link